Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The round was led by Hefei Zhonghe Oupu Medical, with the Health Industry Fund Partnership and Shaanxi Investment Fund participating as leading investors. The funds raised will be directed towards the research and development of integrated equipment for minimally invasive and photodynamic diagnosis and treatment, photobiological regulation, and other advanced medical technologies, as well as supporting clinical studies.
Blueray Med’s Groundbreaking Laser Surgical Systems
Established in 2016, Blueray Med has made significant strides in the field of laser medicine. The company takes pride in its world-first 30W blue laser surgical system, a Category III product that received approval in China in November 2021. Furthermore, Blueray Med has developed the world’s largest 200W blue laser surgical system, which was approved in April 2022. These innovations position the company at the forefront of laser medicine technology.
Expanding R&D and Clinical Studies
The proceeds from the Series A+ financing will play a crucial role in advancing Blueray Med’s research and development efforts, enabling the company to refine its existing technologies and explore new applications in minimally invasive procedures and photodynamic treatments. Additionally, the funds will support clinical studies, which are essential for bringing these cutting-edge medical devices to market and improving patient outcomes.-Fineline Info & Tech
